Big Pharma’s R&D spending flatlined in 2022: What it means for the industry —Bluebird Bio submits BLA for sickle cell disease gene therapy—Eli Lilly launches Mounjaro head-to-head trial against Novo Nordisk's Wegovy-- See more on our front page news http://bit.ly/w28kSd #bigpharma #researchanddevelopment #bluebirdbio #sicklecelldisease #genetherapy #obesity #elililly #novonordisk #wegovy #mounjaro #clinicaltrials #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#bigpharma #researchanddevelopment #bluebirdbio #Sicklecelldisease #genetherapy #obesity #elililly #novonordisk #wegovy #mounjaro #clinicaltrials #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
Gene therapy has made some recent progress—is it enough? - Enlarge (credit: MARK GARLICK/SCIENCE PHOTO LIBRARY)
Gene the... - https://arstechnica.com/?p=1882763 #rarediseases #bluebirdbio #genetherapy #features #genetics #medicine #science #history
#history #science #medicine #genetics #features #genetherapy #bluebirdbio #rarediseases
Ars Technica: Gene therapy has made some recent progress—is it enough? https://arstechnica.com/?p=1882763 #Tech #arstechnica #IT #Technology #rarediseases #bluebirdbio #genetherapy #Features #Genetics #medicine #Science #History
#Tech #arstechnica #it #technology #rarediseases #bluebirdbio #genetherapy #features #genetics #medicine #science #history
Amgen to buy Horizon in biotech's biggest deal of 2022 — AbbVie slapped with age discrimination lawsuit, following other pharmas — ASH 2022: Brisol Myers, Roche, Gracell, Bluebird Bio, and more -- See more on our front page news http://bit.ly/w28kSd #amgen #horizontherapeutics #mergersandacquisitions #agediscrimination #abbvie #legal #lawsuits #ash22 #bristolmyerssquibb #bluebirdbio #pharma #pharmanews #biotech #biotechnology #biopharma #cafepharma
#amgen #horizontherapeutics #mergersandacquisitions #agediscrimination #abbvie #legal #lawsuits #ash22 #bristolmyerssquibb #bluebirdbio #pharma #pharmanews #biotech #biotechnology #biopharma #cafepharma
Large pharmas probe takeover of Horizon Therapeutics — Bluebird Bio sells priority review voucher for $102M — Another Twitter blow to science as Musk ends COVID misinformation policy -- See more on our front page news http://bit.ly/w28kSd #mergersandacquisitions #horizonpharma #bluebirdbio #fda #priorityreviewvoucher #twitter #elonmusk #socialmedia #misinformation #covid #covid19 #pharma #pharmanews #biotech #biotechnology #biopharma #cafepharma
#mergersandacquisitions #horizonpharma #bluebirdbio #FdA #priorityreviewvoucher #twitter #elonmusk #socialmedia #misinformation #covid #covid19 #pharma #pharmanews #biotech #biotechnology #biopharma #cafepharma